Anaplastic thyroid cancer
primary cancers, ATCs, cancer, Anaplastic thyroid cancers, thyroid cancers
CANCER, DISEASE, ANAPLASTIC THYROID CANCER, PRIMARY CANCER, THYROID CANCER
Anaplastic thyroid cancers (ATCs) comprise 1% to 10% of all thyroid cancers worldwide. Patients with ATCs have a median survival of 5 to 12 months and a 1-year overall survival of 20% to 40% (We recognize the limitations of our study. This study enrolled a heterogeneous patient population, with a limited number of patients in a variety of primary cancers. Moreover, patients were exposed to a high number of prior therapies, and their physical capability and compliance are relatively poor, thus some patients did not use angiogenesis drugs because of poor performance status, intolerance, financial reasons, or other subjective causes. Furthermore, the immune status of these patients such as PD-L1 expression before and during therapy was not prespecified in our protocol, and whether PD-L1 expression could be consider as a biomarker for the efficacy of the study combination regimen in this challenging disease these warranted further investigation in future trials with larger sample size. Exploring effective predictive biomarkers would be our future work since it is vital to identify which cancer types and populations are particularly suitable for combinatorial approaches.